So Im going to be getting out of one of my investments in another stock soon (not ACRX) and looking for other promising biotechs with catalysts upcoming. (Im a buy and hold type of person btw I dont trade to much...)
Any one have any stocks they are really liking? I am obviously going to be doing my own DD but just thought I would ask the ones who might know best about a certain company for an opinion of a good place to start.
Sorry if you guys think Im negative as well, I dont try to come across that way, I just try to stay realistic.
also if you guys are looking for something that could rival our lovely ACRX soon Id highly recommend checking out GTXI.
phase 3 results will be out in the 3rd quarter (prob end of july early august) and it is fast tracked. I think that it is probably going to be one of my best holding after ACRX once the results are released.
insider ownership is at 70% as well...all buys no sells....
only time will tell but this company has promise. I wont be selling until at least $12/share
I loooove ACRX but have my investments also in GTXI. Love the management and P3 should be clearly met. Muscle wasting in chemotherapy for NSCLC. Take a looked for yourself but looks really good. Also playing ENTIRE bc I love end stage renal chances with an established renal provider already.glta
Although I am on the wrong side of the trade with INSM, it is 20 percent off it's high. P3 data for arikace due out ANY day - perhaps next week. It is a low floater like ACRX; therefore, volume can change the price quite a bit. IMO, if the data is good I look for it to go to 18-20 short ter, if data bad all the way to 5. Most analysts feel confident the data will be good in the TOBI comparator trial. It is an inhaler type delivery of an already approved antibiotic. Also has orphan drug status by the FDA. If data is good, will be the leader in treating cystic fibrosis. Oh, this is an EU trial we are waiting on P3. INSMED.
Check on BDSI it fits a lot of my criteria. 40 mil cash, some revs already, insider and institution ownership, decent little pipeline, partnerships, and most important not a very high valuation of 150mil. Good for 10-25% pop
Disclaimer: I hold zero shares currently. ACRX, MNTA only 2 positions.